Noah Beerman
Chief Executive Officer presso AI Proteins, Inc.
Profilo
Noah D.
Beerman is currently the Chief Executive Officer & Director at AI Proteins, Inc. He previously held positions as the President, Chief Executive Officer & Director at Galena Biopharma, Inc. from 2009 to 2011, the Chief Business Officer & Executive Vice President at Indevus Pharmaceuticals, Inc. from 1997 to 2009, the Chief Operating Officer & Executive Vice President at Fortress Biotech, Inc. from 2011 to 2013, and as the Executive Vice President-Business Development at Poxel SA. He also served as a Director at Trasir Therapeutics, Inc. and as a Vice President at Technology Management & Funding LP.
Mr. Beerman obtained his undergraduate degree from Rochester Christian University.
Posizioni attive di Noah Beerman
| Società | Posizione | Inizio |
|---|---|---|
AI Proteins, Inc.
 AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Chief Executive Officer | 08/08/2023 |
Precedenti posizioni note di Noah Beerman
| Società | Posizione | Fine |
|---|---|---|
| FORTRESS BIOTECH, INC. | Chief Operating Officer | 05/11/2013 |
Galena Biopharma, Inc.
 Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Chief Executive Officer | 31/03/2011 |
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 25/03/2009 |
Trasir Therapeutics, Inc.
 Trasir Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Altamira Therapeutics Ltd., Trasir Therapeutics, Inc. develops specialty pharmaceutical products. The private company is based in Tampa, FL. The company was founded by Samuel A. Wickline. Trasir Therapeutics was acquired by Altamira Therapeutics Ltd. on June 03, 2021 for $4.32 million. | Director/Board Member | - |
| POXEL | Corporate Officer/Principal | - |
Formazione di Noah Beerman
| Rochester Christian University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| FORTRESS BIOTECH, INC. | Health Technology |
| POXEL | Health Technology |
| Aziende private | 5 |
|---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
| Technology Management & Funding LP | |
Trasir Therapeutics, Inc.
Trasir Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Altamira Therapeutics Ltd., Trasir Therapeutics, Inc. develops specialty pharmaceutical products. The private company is based in Tampa, FL. The company was founded by Samuel A. Wickline. Trasir Therapeutics was acquired by Altamira Therapeutics Ltd. on June 03, 2021 for $4.32 million. | Health Technology |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Health Technology |
- Borsa valori
- Insiders
- Noah Beerman
